Skip to main content
. 2019 Oct 2;11(10):1482. doi: 10.3390/cancers11101482

Figure 3.

Figure 3

Characterization of HMGA2-overexpressing colorectal cancer cells. (A) The mRNA and protein expressions of HMGA2 in DLD-1-Vector and DLD-1-HMGA2 cells were analyzed by qPCR and Western blotting, respectively; (B) the growth rate of DLD-1-Vector and DLD-1-HMGA2 cells was measured by cell counts at 1–4 days; (C) the growth rate of DLD-1-Vector and DLD-1-HMGA2 cells on mice was measured using xenograft; (D) DLD-1-Vector and DLD-1-HMGA2 cells were treated with various doses of netropsin for 72 h. The cell viability was analyzed by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay; (E) the protein expression of HMGA2 in DLD-1-Vector, DLD-1-HMGA2, and HCT116 cells was analyzed by Western blot analysis; (F) DLD-1 and HCT116 cells were treated with various doses of netropsin for 72 h. The cell viability was analyzed by an MTT assay.